Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The EFOMP working group on the Role of Medical Physics Experts (MPEs) in Clinical Trials was established in 2010, with experts from across Europe and different areas of medical physics. Their main aims were: (1) To develop a consensus guidance document for the work MPEs do in clinical trials across Europe. (2) Complement the work by American colleagues in AAPM TG 113 and guidance from National Member Organisations. (3) To cover external beam radiotherapy, brachytherapy, nuclear medicine, molecular radiotherapy, and imaging. This document outlines the main output from this working group. Giving guidance to MPEs, and indeed all Medical Physicists (MP) and MP trainees wishing to work in clinical trials. It also gives guidance to the wider multidisciplinary team, advising where MPEs must legally be involved, as well as highlighting areas where MPEs skills and expertise can really add value to clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmp.2024.104821 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
INVESTIGATIONAL AGENTS FOR ISCHAEMIC CARDIOMYOPATHY TREATMENT: PRECLINICAL AND EARLY PHASE INSIGHTS.
Expert Opin Investig Drugs
September 2025
Heart Failure Clinic, Division of Cardiology, Alessandro Manzoni Hospital, ASST Lecco, Lecco, Italy.
Introduction: Ischemic heart disease (IHD) constitutes the most prevalent form of cardiac disease in the general population. Although current therapeutic interventions have significantly improved both quality of life and survival rates, no available treatment can reverse the loss of cardiomyocytes resulting from ischemic injury. Existing therapies are limited to attenuating myocardial damage, reducing its extent, and mitigating its clinical consequences.
View Article and Find Full Text PDFEffectiveness of Platelet-Rich Fibrin for Temporomandibular Disorders Management: A Systematic and Meta-Analysis.
Oral Dis
September 2025
Graduate Program in Dentistry, Federal University of Pelotas, Pelotas, Brazil.
Objective: This study systematically reviewed the effect of intra-articular injection (IAI) of platelet-rich fibrin (i-PRF), alone or combined with arthrocentesis or arthroscopy, in managing painful articular temporomandibular disorders (TMD) and improving maximum mouth opening (MMO).
Materials And Methods: A systematic literature search was conducted in five databases, identifying randomized and nonrandomized clinical trials focusing on minimally invasive TMJ interventions using i-PRF. Meta-analyses were performed with a random-effects model for studies reporting similar outcomes, visual analog scale (VAS) scores for pain, and MMO values.
PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
Clin Transl Oncol
September 2025
Spanish Society of Medical Oncology (SEOM) Thrombosis and Cancer Group, Madrid, Spain.
Purpose: To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP).
Methods/patients: A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT.
Advances and prospects of ergothioneine in the treatment of cognitive frailty.
Ann Med
December 2025
School of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: To review the biological functions of ergothioneine (ERGO), its correlation with plasma levels in cognitive frailty, and research progress in treating frailty and cognitive impairment, with the aim of providing a reference for ERGO application in cognitive frailty treatment.
Methods: A comprehensive review of existing literature on ERGO's chemical structure, sources, antioxidant and anti-inflammatory effects, and its role in cognitive frailty was conducted. Clinical trial data and metabolomic studies were also analyzed to understand ERGO's therapeutic potential.
Immunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.
Future Sci OA
December 2025
Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Background: Smoking induces inflammation in the heart and intima layer of blood vessels by activating nuclear factor kappa B, which controls the transcription of immunoglobulin free light chain (FLC)-κ. FLC levels are indicative of higher mortality in the overall population and poorer prognoses in cardiovascular diseases. This study aimed to analyze the effect of smoking cessation (SC) on the levels of FLCs and markers of inflammation and heart failure.
View Article and Find Full Text PDF